This 2020 electron microscope image provided by the National Institute of Allergy and Infectious Diseases - Rocky Mountain Laboratories shows SARS-CoV-2 virus particles which cause COVID-19, isolated from a patient in the U.S., emerging from the surface of cells cultured in a lab. According to a study released in The Lancet Global Health on Wednesday, Oct. 27, 2021, Fluvoxamine, a cheap antidepressant, reduced the need for hospitalization among high-risk adults with COVID-19. (NIAID-RML via AP)
By Carla K. Johnson
A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus.
Researchers tested the pill used for depression and obsessive-compulsive disorder because it was known to reduce inflammation and looked promising in smaller studies.
They've shared the results with the U.S. National Institutes of Health, which publishes treatment guidelines, and they hope for a World Health Organization recommendation.
“If WHO recommends this, you will see it widely taken up,” said study co-author Dr. Edward Mills of McMaster University in Hamilton, Ontario, adding that many poor nations have the drug readily available. “We hope it will lead to a lot of lives saved.”
The pill, called fluvoxamine, would cost $4 for a course of COVID-19 treatment. By comparison, antibody IV treatments cost about $2,000 and Merck's experimental antiviral pill for COVID-19 is about $700 per course. Some experts predict various treatments eventually will be used in combination to fight the coronavirus.
Researchers tested the antidepressant in nearly 1,500 Brazilians recently infected with coronavirus who were at risk of severe illness because of other health problems, such as diabetes. About half took the antidepressant at home for 10 days, the rest got dummy pills. They were tracked for four weeks to see who landed in the hospital or spent extended time in an emergency room when hospitals were full.
In the group that took the drug, 11% needed hospitalization or an extended ER stay, compared to 16% of those on dummy pills.
The results, published Wednesday in the journal Lancet Global Health, were so strong that independent experts monitoring the study recommended stopping it early because the results were clear.
Questions remain about the best dosing, whether lower risk patients might also benefit and whether the pill should be combined with other treatments.
The larger project looked at eight existing drugs to see if they could work against the pandemic virus. The project is still testing a hepatitis drug, but all the others — including metformin, hydroxychloroquine and ivermectin — haven't panned out.
The cheap generic and Merck's COVID-19 pill work in different ways and “may be complementary,” said Dr. Paul Sax of Brigham and Women’s Hospital and Harvard Medical School, who was not involved in the study. Earlier this month, Merck asked regulators in the U.S. and Europe to authorize its antiviral pill.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
Jeff Bezos’ aerospace company Blue Origin successfully held a fourth civilian launch into space on Thursday. Former NASA Astronaut, Leroy Chiao, joined Cheddar News to talk about the significance of this launch for the future of civilian launches and to discuss the issue of safety. "This is opening space up to more people, raising more awareness, which is good for the entire industry," Chiao said. He also discussed the nature of pricing the tickets for space tourism.
The most popular and most valuable cryptocurrency is also the least eco-friendly - data shows that Bitcoin mining generates the same amount of carbon emissions as the entire country of Thailand. According to nonprofit Fair Planet, 96 million tons of carbon dioxide emissions come from Bitcoin mining every year. Now, a consortium of climate activist groups is calling on the Bitcoin industry to cut its energy use by making changes to its software code. Michael Brune, former executive director of the Sierra Club, joins Cheddar News' Closing Bell to discuss.
A cannabis software startup is offering a first-of-its-kind perk for its employees - reimbursements for legal cannabis purchases. Jointly Better bills itself as an experience-based cannabis wellness tracker and product platform. In an attempt to attract top talent, the company will reimburse up to $150 a month for its workers' lawful cannabis purchases. David Kooi, co-founder and CEO of Jointly, joins Cheddar News' Closing Bell to discuss.
Catching you up on what you need to know on Mar 31, 2022, with updates on Biden's push for more COVID funding, a wave of storms hammering the South, Etsy sellers going on strike, and more.
President Joe Biden has gotten a second booster dose of the Pfizer COVID vaccine, and he used the occasion Wednesday to call on Congress to pass billions of dollars in additional funding to fight the pandemic.
Catching you up on what you need to know on March 30, 2022, with updates on what is happening in Kyiv, the FDA releases plans for a fourth dose of COVID vaccines, COVID subvariant BA.2 becomes dominant variant in the U.S., employees at Conde Nast form a union, and more.
A NASA astronaut is back on Earth after a yearlong, record-setting spaceflight. He caught a Russian ride from the International Space Station on Wednesday with two cosmonauts.
Blue Origin is gearing up for its first launch of the year, set for March 31st, but it's not the only one. NASA is also days away from making history with its first private mission to the International Space Station. Three amateur astronauts, who have each paid about $55 million for their seat, will reach the ISS and spend eight days at the off-earth outpost. Jim Cantrell, CEO and co-founder of Phantom Space, joins Cheddar News to discuss what the future of space tourism may look like.
